Pfizer Found Guilty In Adalat CC Case
A US federal court has ruled against Pfizer in its lawsuit with Miles, a unit of Germany's Bayer AG, concerning promotion of the companies' nifedipine products. The court found Pfizer guilty of making false and misleading comments about Miles' Adalat CC. Pfizer manufactures a nifedipine product called Procardia XL.
In October 1993, Pfizer sued Miles for false advertising and pricing claims and a misleading pharmacy-information program for Adalat CC. Miles promptly filed a counterclaim against Pfizer saying that it had made false and misleading statements about Adalat CC.
The verdict is the latest in a series of disputes between the companies. In April, Miles agreed to stop offering pharmacists in the USA a bounty to switch patients from Procardia XL to Adalat CC (Marketletter April 18).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze